Table 3.
Distribution of LI-RADS categories and imaging features in HCC with low (<40%) and high (≥40%) FAI
| FAI < 40% (n = 51) | FAI ≥ 40% (n = 20) | p-value | |
| LI-RADS diagnostic category | |||
| LR-3 | 4 (8%) | 0 (0%) | 0.377 |
| LR-4 | 16 (31%) | 6 (30%) | |
| LR-5 | 31 (61%) | 14 (70%) | |
| LI-RADS imaging features | |||
| Size (mm) mean ± standard deviation | 36±30 | 56±42 | 0.005 |
| Arterial phase hyperenhancement | 0.262 | ||
| Present | 44 (86%) | 15 (75%) | |
| Absent | 7 (14%) | 5 (25%) | |
| Washout appearance | 0.429 | ||
| Present | 36 (71%) | 16 (80%) | |
| Absent | 15 (29%) | 4 (20%) | |
| Capsule appearance | 0.390 | ||
| Present | 21 (41%) | 6 (30%) | |
| Absent | 30 (59%) | 14 (70%) | |
| Mosaic architecture | 0.028 | ||
| Present | 16 (31%) | 12 (60%) | |
| Absent | 35 (69%) | 8 (40%) | |
| Tumor in vein | 0.544 | ||
| Present Absent |
|||
FAI, fractional allelic imbalance; HCC, hepatocellular carcinoma; LI-RADS, liver imaging reporting and data system.